IDEXX LABORATORIES INC. $36 (Nasdaq symbol IDXX; Aggressive Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 59.1 million; Market cap: $2.1 billion; Price-to-sales ratio: 2.2; WSSF Rating: Average) makes equipment that veterinarians use to detect diseases in animals. Idexx also makes systems that detect contaminants in water and milk. Idexx spends roughly 7% of its revenue on research, which hurts its profits. But this spending gives it plenty of new products to spur sales. Last year, Idexx launched new versions of its two top-selling systems: Catalyst Dx (which analyzes blood and urine), and SNAPshot Dx (which tests for thyroid and liver disorders). Thanks to strong demand for these new products, Idexx’s sales rose 11%, to $1 billion in 2008 from $922.6 million in the previous year. Earnings before several one-time items (mainly the sale of part of its animal drug business) rose 16%, to $118.3 million from $102 million. Earnings per share rose 20.3%, to $1.90 from $1.58 on fewer shares outstanding. Idexx ended 2008 with cash of $78.9 million, or $1.33 a share. Its long-term debt is just $5.1 million. The stock trades at a high 19.6 times Idexx’s likely 2009 earnings of $1.84 a share. That makes it vulnerable if these earnings fail to meet expectations. Idexx is a hold.
IDEXX LABORATORIES INC. $36 - Nasdaq symbol IDXX
A professional investment analyst for more than 30 years, Pat has developed a stock-selection technique that has proven reliable in both bull and bear markets. His proprietary ValuVesting System™ focuses on stocks that provide exceptional quality at relatively low prices. Many savvy investors and industry leaders consider it the most powerful stock-picking method ever created.